Blank Fabian, Fytianos Kleanthis, Seydoux Emilie, Rodriguez-Lorenzo Laura, Petri-Fink Alke, von Garnier Christophe, Rothen-Rutishauser Barbara (2017), Interaction of biomedical nanoparticles with the pulmonary immune system., in Journal of Nanobiotechnology
, 15(6), 1-9.
Fytianos Kleanthis, Drasler Barbara, Blank Fabian, von Garnier Christophe, Seydoux Emilie, Rodriguez-Lorenzo Laura, Petri-Fink Alke, Rothen-Rutishauser Barbara (2016), Current in vitro approaches to assess nanoparticle interactions with lung cells., in Nanomedicine (Lond).
, 11(18), 2457-2469.
Seydoux Emilie, Rodriguez-Lorenzo Laura, Blom Rebecca A M, Stumbles Philip A, Petri-Fink Alke, Rothen-Rutishauser Barbara M, Blank Fabian, von Garnier Christophe (2016), Pulmonary delivery of cationic gold nanoparticles boost antigen-specific CD4(+) T Cell Proliferation., in Nanomedicine : nanotechnology, biology, and medicine
, 12(7), 1815-1826.
Peter Wick, Savvina Chortarea, Olivier Guenat, Matthias Roesslein, Janick Stucki, Alke Petri-Fink, Barbara Rothen-Rutishauser (2015), In vitro-ex vivo model systems for nanosafety assessment, in Eur J Nanomed
, 7(3), 169-179.
Fytianos Kleanthis, Rodriguez-Lorenzo Laura, Clift Martin J. D., Blank Fabian, Vanhecke Dimitri, von Garnier Christophe, Petri-Fink Alke, Rothen-Rutishauser Barbara (2015), Uptake efficiency of surface modified gold nanoparticles does not correlate with functional changes and cytokine secretion in human dendritic cells in vitro, in NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE
, 11(3), 633-644.
Peter Wick, Stephanie Grabmueller, Alke Petri-Fink, Barbara Rothen-Rutishauser (2014), Advanced human in vitro models to assess metal-oxide nanoparticle-cell interactions, in MRS Bulletin
, 39(11), 984-989.
Rodriguez-Lorenzo L., Fytianos K., Blank F., von Garnier C., Rothen-Rutishauser B., Petri-Fink A. (2014), Fluorescence-encoded gold nanoparticles: library design and modulation of cellular uptake into dendritic cells, in Small
, 10, 1341-1350.
Vanhecke D., Rodriguez-Lorenzo L., Clift M.J., Blank F., Petri-Fink A., Rothen-Rutishauser B. (2014), Quantification of nanoparticles at the single-cell level: an overview about state-of-the-art techniques and their limitations, in Nanomedicine
, 9, 1885-1900.
Seydoux E., Rothen-Rutishauser B., Nita I.M., Balog S., Gazdhar A., Stumbles P.A., Petri-Fink A., Blank F., von Garnier C. (2014), Size-dependent accumulation of particles in lysosomes modulates dendritic cell function through impaired antigen degradation, in Int J Nanomedicine
, 9, 3885-3902.
Behra R., Sigg L., Clift M.J., Herzog F., Minghetti M., Johnston B., Petri-Fink A., Rothen-Rutishauser B. (2013), Bioavailability of silver nanoparticles and ions: from a chemical and biochemical perspective, in J R Soc Interface
, 10, 20130396-20130396.
Mahmoudi Morteza, Hofmann Heinrich, Rothen-Rutishauser Barbara, Petri-Fink Alke (2012), Assessing the in vitro and in vivo toxicity of superparamagnetic iron oxide nanoparticles., in Chemical reviews
, 112(4), 2323-38.
Petri-Fink Alke, Rothen-Rutishauser Barbara (2012), Nanoparticles and cells: an interdisciplinary approach., in Chimia
, 66(3), 104-9.
Blank Fabian, Gerber Peter, Rothen-Rutishauser Barbara, Sakulkhu Usawadee, Salaklang Jatuporn, De Peyer Karin, Gehr Peter, Nicod Laurent P, Hofmann Heinrich, Geiser Thomas, Petri-Fink Alke, Von Garnier Christophe (2011), Biomedical nanoparticles modulate specific CD4+ T cell stimulation by inhibition of antigen processing in dendritic cells., in Nanotoxicology
, 5(4), 606-21.
Fytianos Kleanthis, Chortarea Savvina, Rodriguez-Lorenzo Laura, Blank Fabian, von Garnier Christophe, Petri-Fink Alke, Rothen-Rutishauser Barbara, Aerosol Delivery of Functionalized Gold Nanoparticles Target and Activate Dendritic Cells in a 3D Lung Cellular Model., in ACS Nano
, in press.
Fytianos K., Rodriguez-Lorenzo L., Clift M.J., Blank F., Vanhecke D., von Garnier C., Petri-Fink A., Rothen-Rutishauser B., Uptake efficiency of surface modified gold nanoparticles does not correlate with functional changes and cytokine secretion in human dendritic cells in vitro, in Nanomedicine: NBM
The aetiology of allergic asthma is multi-factorial and triggered by a skewed immune response to innocuous airborne allergens such as dust mite allergen and pollen. Despite intense research, rates of allergy and allergy-induced asthma continue to rise in most industrialised nations and also in emerging countries. Nanoparticles (NP) synthesised by nanotechnology may have many different shapes and chemical compositions, therefore their properties can be specifically designed for clinical diagnostic and therapeutic applications. Recent studies have shown that NP can stimulate or suppress various immune response pathways; however the effects of NP on the immune system in relation to the particle properties (size, surface modification, solubility and shape) are unknown to date.In order to harness the unique properties of NP for novel clinical applications in the treatment of allergic respiratory disease, we propose to develop and utilise specifically designed NP to investigate immune-modulatory and anti-inflammatory effects in the lung with various experimental approaches: (I) In vitro systems of the human lung to evaluate the trafficking of NP by macrophages (innate immune system) and dendritic cells (adaptive immune system), as well as their potentially associated immune-modulatory effects and nano-immunotoxicity.(II) In vivo assays, i.e. allergic respiratory disease models, to evaluate the immune-modulatory potential of NP and adverse nano-immunotoxic effects.The aim of the proposed project is to specifically evaluate designed NP as pulmonary anti-allergic nanovaccines for the treatment of allergic asthma by utilising established methods to investigate immune-modulatory effects and study possible associated health risks such as nano-immunotoxicity.